221 related articles for article (PubMed ID: 33787380)
1. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature.
Singh B; Kaur P; Maroules M
J Investig Med High Impact Case Rep; 2021; 9():2324709621992207. PubMed ID: 33787380
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
6. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
7. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
[TBL] [Abstract][Full Text] [Related]
8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
9. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
10. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
Al Zahrani A; Alfakeeh A
J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series.
Sakaguchi K; Satoh T; Kawaguchi S; Aoyama T; Asahara K; Endo S; Shirane N; Kanemoto H; Oba N; Ohno K
Clin J Gastroenterol; 2024 Jun; 17(3):515-522. PubMed ID: 38502472
[TBL] [Abstract][Full Text] [Related]
12. The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Takeuchi Y; Nouso K; Fujioka SI; Kariyama K; Kobashi H; Uematsu S; Moriya A; Hagihara H; Takabatake H; Nakamura S; Yabushita K; Kikuchi T; Oyama A; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A
Cancer Med; 2023 Sep; 12(17):17559-17568. PubMed ID: 37537956
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
14. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
Liu X; Lu Y; Qin S
Future Oncol; 2021 Jun; 17(17):2243-2256. PubMed ID: 33663220
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
17. Two cases of severe oral mucositis caused by atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma.
Shimoji Y; Yamauchi R; Shibata K; Fukuda H; Fukunaga A; Tanaka T; Takata K; Yokoyama K; Shakado S; Hirai F
Clin J Gastroenterol; 2024 Jun; 17(3):523-529. PubMed ID: 38512635
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
[TBL] [Abstract][Full Text] [Related]
19. [Our Experience with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma].
Shimizu J; Yamashita M; Odagiri K; Takeyama H; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Dono K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1513-1515. PubMed ID: 38303325
[TBL] [Abstract][Full Text] [Related]
20. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]